Despite recent advances in therapy, multiple myeloma (MM) remains an incurable disease. MM-associated osteolytic bone disease (OBD), which occurs in more than 80% of MM patients, is a major cause of morbidity and mortality in MM and the development of new therapeutic strategies is of great interest.
INTRODUCTION MATERIALS AND METHODS
Saracatinib. Saracatinib was kindly provided by AstraZeneca. For in vitro studies a stock solution was prepared in DMSO. For in vivo studies, saracatinib was dissolved in 0.5% hydroxy-propyl-methyl-cellulose containing 0.1% Tween-80. Mice received a daily dose of 25mg/kg saracatinib or vehicle by oral gavage. OCL assays. Murine bone marrow monocyte-derived OCLs (mOCL) were generated in differentiation medium supplemented with 100ng/ml M-CSF and 100ng/ml sRANKL. RAW264.7 cultures: 30ng/ml sRANKL. TRAP activity was assessed with the Leukocyte TRAP kit (Sigma-Aldrich). Resorption was assessed on Osteo Assay plates (Corning) with a Von Kossa staining. OBL assays. Murine mesenchymal stem cell (mMSC)-and MC3T3-E1-derived OBLs were generated in differentiation medium supplemented with 50mg/ml ascorbic acid and 2mM b-glycerolphosphate. Von Kossa staining was performed to detect mineralized matrix and Sirius red staining to detect collagen. Murine MM models. 2.5*10 5 5TGM.1GFP+ cells were injected i.v. in C57BL/KalwRij mice. 30 days post-injection, the mice were sacrificed and bone marrow plasmocytosis was determined by FACS. The 5T2MM model is propagated by the transfer of 2*10 6 cells from diseased mice in younger syngeneic C57BL/KalwRij mice. 10 days post-transfer, the mice were sacrificed and bone marrow plasmocytosis was determined by staining cytosmears with May-Grunwald-Giemsa. In both models, spleens were weighted at sacrifice. mCT. mCT was performed on a SkyScan1172 scanner (Bruker) with the following settings: 50kV/200mA, 0.5mm aluminum filter, 5 mm 2 pixel size, 0.4 o rotation. Morphometric analyses of trabecular and cortical bone was performed on proximal tibias and distal femurs respectively. Immunohistomorphometry. TRAP (OCL) and Toluidine blue (OBL) stainings were performed on methyl-methacrylate-embedded bone sections. 
RESULTS

Saracatinib inhibits osteoclast differentiation and function in vitro
Saracatinib inhibits collagen secretion by osteoblasts and alters matrix mineralization in vitro Figure (A)+(B) Saracatinib (S) inhibits MC3T3-E1-and primary mMSC-derived OBL collagen secretion (Sirius red staining). (A)+(B) Saracatinib alters MC3T3-E1-and primary MSC-derived OBL matrix mineralization (Von Kossa staining). (C) mRNA expression of OBL markers (MC3T3-E1 cells, qPCR).
Saracatinib limits the development of osteolytic bone disease in multiple myeloma
CONCLUSIONS
This study further establishes SRC inhibition as a promising approach for the treatment of MM-associated OBD. We show a potent inhibitory effect of the SRC kinase inhibitor saracatinib on the development of OBD in both a prophylactic (5TGM.1) and therapeutic (5T2MM) setting. Similar to the OCL phenotype in Src-/-mice (Boyce et al., 1992), this likely occurs through an impairment of bone resorption.
Our study warrants the evaluation of bone parameters in MM patients treated with saracatinib or with novel similar compounds such as AZD0424 (clinicaltrials.gov: NCT01668550).
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